Latest Insider Transactions at Caribou Biosciences, Inc. (CRBU)
This section provides a real-time view of insider transactions for Caribou Biosciences, Inc. (CRBU). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Caribou Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Caribou Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2024
|
Jason O'Byrne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+35.78%
|
-
|
|
Feb 20
2024
|
Ruhi Ahmad Khan Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+50.0%
|
-
|
|
Feb 20
2024
|
Barbara G Mcclung Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+7.46%
|
-
|
|
Feb 20
2024
|
Steven Kanner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+7.86%
|
-
|
|
Feb 20
2024
|
Rachel E. Haurwitz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
118,700
+42.79%
|
-
|
|
Feb 06
2024
|
Steven Kanner Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,577
+7.95%
|
$61,154
$2.69 P/Share
|
|
Jun 08
2023
|
Rachel E. Haurwitz President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.0%
|
$20,000
$2.96 P/Share
|
|
Mar 20
2023
|
Rachel E. Haurwitz President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.0%
|
$20,000
$2.96 P/Share
|
|
Jan 19
2023
|
Syed Ali Aamir Rizvi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,627
-8.66%
|
$33,762
$6.31 P/Share
|
|
Dec 02
2022
|
Steven Kanner Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,401
+6.21%
|
$42,802
$2.69 P/Share
|
|
Oct 06
2022
|
Ryan Fischesser VP of Finance and Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
5,678
+2.42%
|
$17,034
$3.4 P/Share
|
|
Oct 06
2022
|
Ryan Fischesser VP of Finance and Controller |
SELL
Open market or private sale
|
Direct |
10,000
-8.31%
|
$100,000
$10.8 P/Share
|
|
Sep 15
2022
|
Barbara G Mcclung Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,595
+3.42%
|
$55,190
$2.69 P/Share
|
|
Aug 25
2022
|
Steven Kanner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
43,248
-12.52%
|
$475,728
$11.22 P/Share
|
|
Aug 25
2022
|
Steven Kanner Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,248
+11.13%
|
$86,496
$2.69 P/Share
|
|
Aug 22
2022
|
Ryan Fischesser VP of Finance and Controller |
BUY
Grant, award, or other acquisition
|
Direct |
4,848
+3.87%
|
-
|
|
May 13
2022
|
Steven Kanner Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
74,420
+10.37%
|
$148,840
$2.25 P/Share
|
|
May 09
2022
|
Rachel E. Haurwitz President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+33.33%
|
$20,000
$2.96 P/Share
|
|
May 05
2022
|
Ryan Fischesser VP of Finance and Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,274
+0.98%
|
$6,822
$3.4 P/Share
|
|
Mar 15
2022
|
Ryan Fischesser VP of Finance and Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,274
+1.0%
|
$6,822
$3.4 P/Share
|
|
Mar 04
2022
|
Steven Kanner Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,720
+2.29%
|
$32,160
$3.4 P/Share
|
|
Feb 08
2022
|
Jason O'Byrne Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,336
+50.0%
|
$97,344
$4.11 P/Share
|
|
Jan 26
2022
|
Rachel E. Haurwitz President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+0.3%
|
$20,000
$2.96 P/Share
|
|
Jan 25
2022
|
Syed Ali Aamir Rizvi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+48.0%
|
-
|
|
Jan 11
2022
|
Ryan Fischesser VP of Finance and Controller |
BUY
Open market or private purchase
|
Direct |
7,387
+3.22%
|
$22,161
$3.4 P/Share
|
|
Dec 20
2021
|
Ryan Fischesser VP of Finance and Controller |
BUY
Open market or private purchase
|
Direct |
1,136
+1.1%
|
$2,272
$2.69 P/Share
|
|
Dec 07
2021
|
Barbara G Mcclung Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
6,127
+0.86%
|
$12,254
$2.69 P/Share
|
|
Oct 20
2021
|
Barbara G Mcclung Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
9,219
+1.31%
|
$18,438
$2.69 P/Share
|
|
Oct 12
2021
|
Steven Kanner Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
114,860
+13.32%
|
$229,720
$2.1 P/Share
|
|
Oct 11
2021
|
Ryan Fischesser VP of Finance and Controller |
BUY
Open market or private purchase
|
Direct |
1,746
+1.71%
|
$3,492
$2.69 P/Share
|
|
Jul 27
2021
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
3,323,284
+46.69%
|
-
|